Caplin Point posted strong Q1 FY26 growth with rising revenue, margin expansion, and a robust presence in global pharma markets.

• Revenue rose 11.2% YoY to Rs 510.2 crore; PAT up 20.7% YoY at Rs 150.8 crore; EBITDA margin hit 37.7%.
• 79% of revenue came from Latin America and Africa; the US market contributed 21%, showing balanced global reach.
• Chairman highlights expansion in Mexico, Chile, USA; focus on biosimilars and strategic manufacturing in LatAm, US.